# **Supplementary Online Content**

Ossenkoppele R, Smith R, Mattsson-Carlgren N, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. *JAMA Neurol*. Published online June 28, 2021. doi:10.1001/jamaneurol.2021.1858

**eFigure 1.** Replication of Figure 1 (PET vs MRI Comparison) Using [<sup>18</sup>F]RO948 PET in an Independent Dataset

**eFigure 2.** [<sup>18</sup>F]Flortaucipir SUVR in Entorhinal Cortex and Hippocampal Volumes as Predictors of Change in MMSE

**eFigure 3.** Replication of eFigure 2 With [<sup>18</sup>F]RO948 PET in an Independent Dataset **eFigure 4.** [<sup>18</sup>F]Flortaucipir SUVR in Braak V/VI ROIs and Whole Brain Cortical Thickness as Predictors of Change in MMSE

**eFigure 5.** Replication of eFigure 4 With [<sup>18</sup>F]RO948 PET in an Independent Dataset **eFigure 6.** Replication of Figure 2 (Mediation Analysis) Using [<sup>18</sup>F]RO948 PET in an Independent Dataset

eTable 1. Participant Characteristics for the Discovery Cohort (A) vs the Replication Cohort (B)

eTable 2. Participant Characteristics for the Different Cohorts

**eTable 3.** Bootstrapping of *R*<sup>2</sup> Values From Tau PET vs MRI Models Predicting MMSE Change

**eTable 4.** Linear Mixed Models With [<sup>18</sup>F]RO948 PET and MRI as Predictors of Change in MMSE

**eTable 5.** Bootstrapping of *R*<sup>2</sup> Values From Tau PET vs Amyloid PET Models Predicting MMSE Change

**eTable 6.** Linear Mixed Models With [<sup>18</sup>F]Flortaucipir PET and Amyloid PET as Predictors of Change in MMSE

**eFigure 7.** Replication of Figure 3 (Associations With Age, Sex, and APOE) Using [<sup>18</sup>F]RO948 PET in an Independent Dataset

eAppendix. ADNI Investigators

This supplementary material has been provided by the authors to give readers additional information about their work.



eFigure 1. Replication of Figure 1 (PET vs MRI Comparison) Using [<sup>18</sup>F]RO948 PET in an Independent Dataset

Graphs represent associations between baseline [<sup>18</sup>F]RO948 (tau) PET uptake in a temporal region-of-interest (upper panel), cortical thickness in an Alzheimer's disease signature region defined on MRI (middle panel) and Amyloid PET (bottom panel) with annual slopes of Mini-Mental State Examination scores across all participants (in black),  $A\beta$ + Alzheimer's disease dementia (in green),  $A\beta$ + mild cognitive impairment (in blue),  $A\beta$ mild cognitive impairment (in orange),  $A\beta$ + cognitively unimpaired individuals (in red) and  $A\beta$ - cognitively unimpaired individuals (in purple). Model outputs are derived from a linear regression model between baseline tau PET/MRI/amyloid PET and MMSE slopes, adjusted for age, sex, education and cohort. R<sup>2</sup> values are provided for the full model (including covariates), and T and p-values represent the interaction between the imaging modality and time. Note that amyloid-PET was only available in 5 participants with AD dementia of the Swedish BioFINDER-2 study and therefore now scatterplot was included for this group.







eFigure 3. Replication of eFigure 2 With [<sup>18</sup>F]RO948 PET in an Independent Dataset



eFigure 4. [18F]Flortaucipir SUVR in Braak V/VI ROIs and Whole Brain Cortical Thickness as Predictors of Change in MMSE



eFigure 5. Replication of eFigure 4 With [18F]RO948 PET in an Independent Dataset

© 2021 Ossenkoppele R, et al. JAMA Neurology.

eFigure 6. Replication of Figure 2 (Mediation Analysis) Using [18F]RO948 PET in an Independent Dataset



Path diagrams indicate whether AD-signature cortical thickness mediates the associations between baseline [ $^{18}$ F]RO948 SUVR in the temporal meta-ROI and MMSE slopes, adjusting for age, sex, education and *APOE*  $\epsilon$ 4 status. The direct effect (i.e., coefficient: c') reflects the extent to which MMSE slopes change when baseline tau PET increases by one unit while baseline cortical thickness remains unaltered. The indirect effect (i.e., coefficient: a<sub>1</sub>·b<sub>1</sub>) reflects the extent to which MMSE slopes changes when baseline tau PET is held constant and baseline cortical thickness changes by the amount it would have changed had baseline tau PET increased by one unit. The coefficient "c" represents the total effect (i.e., direct

© 2021 Ossenkoppele R, et al. JAMA Neurology.

+ indirect effects).

eFigure 7. Replication of Figure 3 (Associations With Age, Sex, and APOE) Using [<sup>18</sup>F]RO948 PET in an Independent Dataset



Linear mixed effects models with random intercepts and fixed slopes were performed to examine whether age (A), sex (B) and *APOE*  $\varepsilon$ 4 status (C) moderate the association between baseline [<sup>18</sup>F]RO948 uptake in a temporal region-of-interest and change over time in Mini-Mental State Examination (MMSE) scores, while adjusting for age, sex, education, cohort and diagnostic group when appropriate. The T- and p-value represent the 3-way interaction Age/Sex/*APOE*  $\varepsilon$ 4 status \* time \* tau PET. Age was entered as continuous variable in the linear mixed effects models, but was dichotomized at age 70 for visualization purposes.

	Whole group	Aβ+ AD dementia	Αβ+ ΜCΙ	Αβ- ΜCΙ	Aβ+ CU	<b>Αβ- CU</b> 358	
Ν	1135	235	190	144	208		
Age, years	71.6 (8.3)	71.7 (8.9) 71.5 (8.2) 70.4 (8.5) 74.3 (		74.3 (6.3)	70.5 (8.5)		
Sex (% male)	52.2	52.2 62.1 48.4		42.4	50.5	52.8	
Education, years	13.7 (6.4)	12.6 (5.1)	12.1 (5.4)	12.7 (5.9)	16.1 (9.4)	14.2 (5.2)	
<i>APOE</i> ε4, % positive 41.1% 67.3		67.3%	60.2%	20.3%	52.5%	17.3%	
MMSE, baseline score	26.7 (3.7)	21.6 (5.1)	27.0 (2.6)	28.1 (1.8)	28.9 (1.2)	29.0 (1.2)	

eTable 1. Participant Characteristics for the Discovery Cohort (A) vs the Replication Cohort (B)

A. [<sup>18</sup>F]Flortaucipir

## B. [<sup>18</sup>F]RO948

	Whole group	Aβ+ AD dementia	Αβ+ ΜCΙ	Αβ- ΜCΙ	Αβ+ CU	Αβ- CU
Ν	296	80	81	28	45	62
Age, years	69.6 (10.3)	74.0 (6.5) 72.1 (7.1) 68.9		68.9 (6.8)	70.2 (9.8)	60.9 (13.6)
Sex (% male)	53.4	47.5	55.6	64.3	44.4	59.7
Education, years	12.6 (4.2)	12.1 (4.7)	12.5 (4.4)	11.8 (2.7)	13.1 (4.1)	13.3 (3.5)
APOE $\varepsilon$ 4, % positive 56.8%		68.4%	66.2%	21.4%	68.9%	37.1%
MMSE, baseline score	25.9 (4.6)	19.9 (4.4)	27.1 (1.9)	27.3 (2.3)	28.8 (1.2)	29.1 (1.1)

Data are presented as mean (standard deviation), unless otherwise stated.

 $A\beta$  = amyloid- $\beta$ , AD = Alzheimer's disease, APOE = Apolipoprotein E, CU = Cognitively unimpaired, MCI = Mild cognitive impairment, MMSE = Mini-mental state examination.

### eTable 2. Participant Characteristics for the Different Cohorts

### **BioFINDER-1**:

	Whole groupAβ+ AD dementiaAβ+ MCIAβ- MCI			Aβ+ CU	Αβ- CU	
Ν	136	44	27	1	32	32
Age, years	72.3 (10.3)	71.0 (7.5)	71.0 (7.5) 71.6 (9.5) 66		74.1 (8.0)	73.0 (7.1)
Sex (% male)	54.4	54.4 56.8 66.7 100		100	37.5	56.2
Education, years	12.4 (3.7)	4 (3.7) 12.3 (3.8) 12.4 (3.7) 13.9		13.9	11.9 (3.7)	12.8 (3.8)
APOE ε4, % positive	positive 59.2% 64.9% 80.8% 0%		0%	80.0%	16.1%	
MMSE, baseline score	25.7 (4.7)	20.8 (4.9)	25.8 (2.9)	30.0	28.9 (1.1)	28.8 (1.1)

Seoul:

Whole group		Aβ+ AD dementia Aβ+ MCI		Αβ- ΜCΙ	Aβ+ CU	Aβ- CU	
Ν	161	42	37	16	8	58	
Age, years	69.4 (9.6)     72.7 (9.5)     71.8 (8.6)		71.8 (8.6)	69.8 (9.9)	71.0 (4.4)	65.2 (9.4)	
Sex (% male)	64.0	76.2	54.1	68.1	62.5	60.3	
Education, years	lucation, years 11.5 (4.9)		11.8 (4.6)	10.6 (4.4)	12.5 (4.1)	12.4 (4.4)	
<i>APOE</i> ε4, % positive	35.0%	58.5%	48.6%	12.5%	37.5%	15.5%	
MMSE, baseline score 25.0 (5.0)		19.0 (5.3)	25.4 (3.2)	26.5 (2.3)	27.9 (2.1)	28.3 (1.7)	

## UCSF:

	Whole group	Aβ+ AD dementia	Αβ+ ΜCΙ	Αβ- ΜCΙ	Aβ+ CU	Αβ- CU	
N	44	28	8	6	1	2	
Age, years	63.9 (10.1)	64.6 (10.4) 61.8 (10.0) 67.3 (7.2)		70	60.9 (13.6)		
Sex (% male)	6 male) 61.4		62.5	33.3	100	0	
Education, years	16.9 (2.7)	22.5 (3.9)	17.9 (3.1)	16.8 (1.3)	20.0	18.5 (2.1)	
<i>APOE</i> ε4, % positive 45.7%		52.5%	40.0%	0%	0%	100%	
MMSE, baseline score	24.6 (4.2)	6.4 (2.7)	17.9 (3.1)	16.8 (1.3)	27.0	30.0 (0)	

## ADNI:

	Whole group	Whole group     Aβ+ AD dementia     Aβ+ MCI     Aβ- MCI		Aβ+ CU	Αβ- CU	
Ν	445	17	77	83	116	152
Age, years	71.6 (6.7)	72.1 (10.1)	10.1) 72.0 (6.9) 70.8 (7.8)		73.5 (6.3)	70.4 (5.5)
Sex (% male)	nale) 49.0 35.3 39.0 33.		33.7	57.8	57.2	
Education, years	on, years 16.5 (2.6) 16		15.8 (2.6)	16.5 (2.7)	16.6 (2.4)	16.7 (2.6)
APOE ε4, % positive	<i>DE</i> ε4, % positive 36.2% 76.9% 62.7% 17.5%		17.5%	47.4%	20.1%	
MMSE, baseline score	28.5 (1.9)	22.6 (2.6)	27.7 (2.0)	28.5 (1.4)	29.0 (1.2)	29.2 (1.0)

### <u>AO5:</u>

	Whole group	Aβ+ AD dementia	Αβ+ ΜCΙ	Αβ- ΜCΙ	Aβ+ CU	<b>Αβ- CU</b> 50	
Ν	160	26	41	38	5		
Age, years	71.3 (9.6)	1.3 (9.6) 76.5 (8.2) 72.2 (8.2) 70.3		70.3 (9.7)	77.8 (7.0)	67.9 (10.3)	
Sex (% male)	48.1	57.5	46.3 50.0		40.0	44.0	
Education, years	13.7 (6.4)	12.6 (2.6)	12.6 (2.4)	13.7 (6.7)	13.2 (3.4)	15.2 (9.3)	
<i>APOE</i> ε4, % positive 41.4%		73.1%	55.3%	33.3%	40.0%	19.1%	
MMSE, baseline score	27.4 (3.4)	21.5 (4.1)	27.5 (1.9)	28.2 (1.8)	29.6 (0.6)	29.5(0.5)	

## EXPEDITION-3:

	Whole group	Aβ+ AD dementia Aβ+ MC		Αβ- ΜCΙ	Aβ+ CU	Αβ- CU
Ν	79	79	NA	NA	NA	NA
Age, years	72.4 (7.5)	72.4 (7.5) NA NA			NA	NA
Sex (% male)	nale) 62.0 62.0		NA	NA NA		NA
Education, years	s 14.7 (2.9) 14.7 (2.		NA	NA	NA	NA
APOE ε4, % positive	<i>OE</i> ε4, % positive 74.0% 74.0% NA		NA	NA	NA	
MMSE, baseline score	22.9 (2.0)	22.9 (2.0)	NA	NA	NA	NA

#### BACS:

	Whole group	Aβ+ AD dementia	Αβ+ ΜCΙ	Αβ- ΜCΙ	Aβ+ CU	Αβ- CU	
Ν	110	NA	NA	NA	46	64	
Age, years	77.1 (6.1)	NA NA NA		77.0 (7.2)	77.3 (7.2)		
Sex (% male)	(% male) 40.9		NA	NA	39.1	42.2	
Education, years	18.2 (12.1)	NA	NA	NA	19.4 (18.4)	17.4 (2.8)	
<i>APOE</i> ε4, % positive 26.6%		NA	NA	NA	51.1%	9.4%	
MMSE, baseline score	28.7 (1.2)	NA	NA	NA	28.6 (1.4)	28.8 (1.1)	

#### **BioFINDER-2:**

	Whole group	Aβ+ AD dementia Aβ+ MCI		Αβ- ΜCΙ	Aβ+ CU	Αβ- CU
Ν	296	80	81	28	45	62
Age, years	69.6 (10.3)	74.0 (6.5) 72.1 (7.1) 68.9 (6.8)		70.2 (9.8)	60.9 (13.6)	
Sex (% male)	53.4	47.5	55.6	64.3	44.4	59.7
Education, years	12.6 (4.2)	12.1 (4.7)	12.5 (4.4)	11.8 (2.7)	13.1 (4.1)	13.3 (3.5)
APOE ε4, % positive	<i>POE</i> ε4, % positive 56.8%		68.4% 66.2%		68.9%	37.1%
MMSE, baseline score	25.9 (4.6)	19.9 (4.4)	27.1 (1.9)	27.3 (2.3)	28.8 (1.2)	29.1 (1.1)

Data are presented as mean (standard deviation), unless otherwise stated.

 $A\beta$  = amyloid- $\beta$ , AD = Alzheimer's disease, *APOE* = Apolipoprotein E, CU = Cognitively unimpaired, MCI = Mild cognitive impairment, MMSE = Mini-mental state examination.

	DISCOVER	RY COHORT ([ <sup>1</sup>	<sup>8</sup> F]flortau	ıcipir)	<b>REPLICATION COHORT ([<sup>18</sup>F]RO948)</b>				
	R <sup>2</sup> difference	95% CI	Т	Р	R <sup>2</sup> difference	95% CI	Т	Р	
	PET - MRI				PET - MRI				
Total group	0.099	0.970-0.101	80.3	<0.001	0.137	0.136-0.139	147.9	<0.001	
Aβ+ AD dementia	-0.041	-[0.045-0.036]	-17.2	<0.001	0.134	0.129-1.140	50.6	<0.001	
Αβ+ ΜCΙ	0.104	0.097-0.110	30.8	<0.001	0.086	0.079-0.094	23.1	<0.001	
Αβ+ CU	0.098	0.093-0.103	38.6	<0.001	0.184	0.163-0.206	16.7	<0.001	
Αβ- ΜCΙ	-0.092	-[0.094-0.091]	-114.0	<0.001	-0.047	-[0.048-0.045]	-61.4	<0.001	
Αβ- CU	0.022	0.018-0.025	13.6	<0.001	0.010	0.008-0.011	15.4	<0.001	

eTable 3. Bootstrapping of *R*<sup>2</sup> Values From Tau PET vs MRI Models Predicting MMSE Change

eTable 4. Linear Mixed Models With [<sup>18</sup>F]RO948 PET and MRI as Predictors of Change in MMSE

	β (SE)	Р	$\mathbb{R}^2$	AIC	X <sup>2</sup> for difference	P for difference				
ALL Aβ+ PARTICIPANTS										
Model 1: Age, sex, education, cohort			0.066	3070						
Model 2: Model 1 + Tau PET	-0.22 (0.02)	<0.001	0.596	2775	307.3	<0.001				
Model 3: Model 1 + Tau PET + MRI	-0.22 (0.02)	<0.001	0.729	2633	107.8	<0.001				
Model 2: Model 1 + MRI	0.49 (0.05)	<0.001	0.409	2868	176.2	<0.001				
Model 3: Model 1 + MRI + Tau PET	0.48 (0.05)	<0.001	0.723	2666	205.5	<0.001				
Αβ+ ΑD DEMENTIA										
Model 1: Age, sex, education, cohort			0.152	1187						
Model 2: Model 1 + Tau PET	-0.15 (0.04)	<0.001	0.384	1142	46.8	<0.001				
Model 3: Model 1 + Tau PET + MRI	-0.15 (0.04)	<0.001	0.419	1137	6.6	<0.001				
			•	•						
Model 2: Model 1 + MRI	0.42 (0.14)	0.002	0.282	2265	24.0	<0.001				
Model 3: Model 1 + MRI + Tau PET	0.42 (0.14)	0.002	0.413	1144	22.9	<0.001				
Aβ+ MILD COGNITIVE IMPAIRMENT										
Model 1: Age, sex, education, cohort			0.125	1017						
Model 2: Model 1 + Tau PET	-0.27 (0.05)	<0.001	0.300	973	48.4	<0.001				
Model 3: Model 1 + Tau PET + MRI	-0.27 (0.05	<0.001	0.308	971	1.6	<0.001				
Model 2: Model 1 + MRI	0.35 (0.09)	<0.001	0.210	999	22.9	<0.001				
Model 3: Model 1 + MRI + Tau PET	0.35 (0.09)	<0.001	0.274	988	11.2	<0.001				
Αβ+ COGNITIVELY UNIMPAIRED INDIVIDUA	ALS									
Model 1: Age, sex, education, cohort			0.096	418						
Model 2: Model 1 + Tau PET	-0.25 (0.06)	<0.001	0.382	381	40.3	<0.001				
Model 3: Model 1 + Tau PET + MRI	-0.25 (0.06)	<0.001	0.384	381	1.0	0.311				
Model 2: Model 1 + MRI	0.13 (0.08)	0.098	0.161	414	7.6	0.023				
Model 3: Model 1 + MRI + Tau PET	0.16 (0.08)	0.038	0.318	395	21.3	<0.001				

	DISCOVERY COHORT ([ <sup>18</sup> F]flortaucipir)				REPLICATION COHORT ([ <sup>18</sup> F]RO948)				
	R <sup>2</sup> difference	95% CI	Т	Р	R <sup>2</sup> difference	95% CI	Т	Р	
	$TAU - A\beta$				ΤΑU – Αβ				
Total group	0.181	0.178-0.183	147.1	<0.001	0.139	0.135-0.143	64.5	<0.001	
Aβ+ AD dementia	0.149	0.146-0.153	81.1	<0.001	NA	NA	NA	NA	
Αβ+ ΜCΙ	0.190	0.184-0.196	63.3	<0.001	0.192	0.184-0.199	49.8	<0.001	
Αβ+ CU	0.102	0.098-0.106	47.0	<0.001	0.259	0.240-0.279	26.3	<0.001	
Αβ- ΜCΙ	0.002	0.002-0.003	8.1	<0.001	-0.065	-[0.067-0.063]	-61.5	<0.001	
Αβ- CU	0.034	0.031-0.037	21.7	<0.001	-0.096	-[0.099-0.093]	-63.2	<0.001	

eTable 5. Bootstrapping of *R*<sup>2</sup> Values From Tau PET vs Amyloid PET Models Predicting MMSE Change

# eTable 6. Linear Mixed Models With [<sup>18</sup>F]Flortaucipir PET and Amyloid PET as Predictors of Change in MMSE

	$\beta$ (SE)	Р	<b>R</b> <sup>2</sup>	AIC	X <sup>2</sup> for difference	P for difference					
ALL Aβ+ PARTICIPANTS											
Model 1: Age, sex, education, cohort			0.185	8333							
Model 2: Model 1 + Tau PET	-0.21 (0.02)	<0.001	0.488	7867	470.0	<0.001					
Model 3: Model 1 + Tau PET + Amyloid PET	-0.21 (0.02)	<0.001	0.492	7862	7.1	0.008					
Model 2: Model 1 + Amyloid PET	0.001 (0.0002)	<0.001	0.254	8254	83.7	<0.001					
Model 3: Model 1 + Amyloid PET + Tau PET	0.001 (0.0002)	<0.001	0.463	8001	254.7	<0.001					
Aβ+ AD DEMENTIA											
Model 1: Age, sex, education, cohort			0.196	3129							
Model 2: Model 1 + Tau PET	-0.18 (0.03)	<0.001	0.329	3050	46.8	<0.001					
Model 3: Model 1 + Tau PET + Amyloid PET	-0.18 (0.03)	<0.001	0.329	3052	0.1	0.822					
Model 2: Model 1 + Amyloid PET	-0.0003 (0.0004)	0.386	0.198	3131	1.3	0.522					
Model 3: Model 1 + Amyloid PET + Tau PET	-0.0004 (0.0004)	0.328	0.302	3091	41.8	<0.001					
Aβ+ MILD COGNITIVE IMPAIRMENT											
Model 1: Age, sex, education, cohort			0.225	2855							
Model 2: Model 1 + Tau PET	-0.25 (0.03)	<0.001	0.387	2755	104.5	<0.001					
Model 3: Model 1 + Tau PET + Amyloid PET	-0.25 (0.03)	<0.001	0.386	2757	0.0	0.972					
Model 2: Model 1 + Amyloid PET	-0.0007 (0.0003)	0.039	0.237	2852	7.8	0.020					
Model 3: Model 1 + Amyloid PET + Tau PET	-0.0007 (0.0003)	0.032	0.338	2807	46.3	<0.001					
Aβ+ COGNITIVELY UNIMPAIRED INDIVIDUALS											
Model 1: Age, sex, education, cohort			0.095	1680							
Model 2: Model 1 + Tau PET	-0.17 (0.06)	0.004	0.175	1658	25.9	<0.001					
Model 3: Model 1 + Tau PET + Amyloid PET	-0.17 (0.06)	0.004	0.175	1659	0.2	0.694					
Model 2: Model 1 + Amyloid PET	-0.0005 (0.0002)	0.023	0.114	1675	8.4	0.015					
Model 3: Model 1 + Amyloid PET + Tau PET	-0.0005 (0.0002)	0.023	0.168	1662	14.7	<0.001					

#### eAppendix. ADNI Investigators

Michael Weiner Paul Aisen **Ronald Petersen** Clifford R. Jack Jr. William Jagust John Q. Trojanowski Arthur W. Toga Laurel Beckett Robert C. Green Andrew J. Saykin John Morris Leslie M. Shaw Enchi Liu Tom Montine Ronald G. Thomas Michael Donahue Sarah Walter Devon Gessert Tamie Sather Gus Jiminez Danielle Harvey Natthew Bernstein Nick Fox Paul Thompson Norbert Schuff Charles DeCarli Bret Borowski Jeff Gunter Matt Senjem Prashanti Vemuri David Jones Kejal Kantarci Chard Ward Robert A. Koeppe

Norm Foster Eric M. Reiman Kewei Chen Chet Mathis Susan Landau Nigel J. Cairns Erin Householder Lisa T. Reinwald Virginia Lee Magdalena Korecka Michal Figurski Karen Crawford Scott Neu Tatiana M. Foroud Steven Potkin Li Chen Faber Kelley Sungeun Kim Kwangsik Nho Zaven Kachaturian **Richard Frank** Peter J. Snyder Susan Molchan Jeffrey Kaye Joseph Quinn Betty Lind Raina Carter Sara Dolen Lon S. Schneider Sonia Pawluczyk Mauricio Beccera Liberty Teodoro Bryan M. Spann James Brewer Helen Vanderswag Adam Fleisher

Judith L. Heidebrink Joanne L. Ford Sara S. Mason Colleen S. Albers David Knopman Kris Johnson Rachelle S. Doody Javier Villanueva Munir Chowdhury Susan Rountree Mimi Dang Yaakov Stern Lawrence S. Honig Karen L. Bell Beau Ances Maria Carroll Sue Leon Erin Householder Mark A. Mintun Stacy Schneider Angela Oliver Randal Griffith David Clark David Geldmacher John Brockington Erik Roberson Hillel Grossman Effie Mitsis Leyla deToledo-Morrell Raj C. Shah Ranjan Duara Daniel Varon Maria T. Greig Peggy Roberts Marilyn Albert Chiadi Onyike

Daniel D'Agostino Stephanie Kleib James E. Galvin Dana M. Pogorelec Brittany Cerbone Christina A. Michel Henry Rusinek Mony J. De Leon Lidia Glodzik Susan De Santi Murali Doraiswamy Jeffrey R. Petrella Terence Z. Wong Jason H. Karlawish David Wolk Charles D. Smith Greg Jicha Peter Hardy Partha Sinha Elizabeth Oates Gary Conrad Oscar L. Lopez MaryAnn Oakley Donna M. Simpson Anton P. Porsteinsson Bonnie S. Goldstein Kim Martin Kelly M. Makino M. Saleem Ismael Connie Brand Ruth A. Mulnard Gaby Thai Catherina McAdams Ortiz Kyle Womack Dana M. Mathews Mary Quiceno

Ramon Diaz Arrastia Richard King Myron Steiner Kristen Martin Cook Michael Devous Allan I. Levey James J. Lah Janet S. Cellar Jeffrey M. Burns Heather S. Anderson Russell h. Swerdlov Liana Apostolova Kathleen Tingus Ellen Woo Daniel H. Silverman Po H. Lu George Bartzokis Neill R. Graff-Radford Francine Parfitt Tracey Kendall Heather S. Johnson Martin R. Farlow Ann-Marie Hake Brandy R. Matthews Scott Herring Cynthia Hunt Christopher H. van Dyck Richard E. Carson Martyha G. MacAvoy Howard Chertkow Howard Bergman Chris Hosein Sandra Black Bojana Stefanovic Curtis Caldwell Ging Yuek Robin

Howard Feldman Benita Mudge Michele Assaly Past Andrew Kertesz John Rogers Dick Trost Charles Bernick Donna Munic Diana Kerwin Marek M. Mesulam Kristine Lipowski Chuang Kuo Wu Nancy Johnson Carl Sadowsky Walter Martinez Raymond S. Turner Kathleen Johnson Brigid Reynolds Reisa A. Sperling Keith A. Johnson Gad Marshall Meghan Frey Jerome Yesavage Joy L. Taylor Barton Lane Allyson Rosen Jared Tinklenberg Marwan N. Sabbagh Christine M. Belden Sherye A. Sirrel Neil Kowal Ronald Killiany Andrew E. Budson Alexander Norbash Patricia L. Johnson Thomas O. Obisesan

Saba Wolday Joana Allard Alan Lerner Paula Ogrocki Leon Hudson Evan Fletcher Owen Carmichel John Olichney Smita Kittur Michael Borrie T.Y. Lee Rob Bartha Sterling Johnson Sanjay Asthana Cynthia M. Carlsson Steven G. Potkin Adrian Preda Daan Nguyen Pierre Tarlot Stephanie Reeder Vernice Bates Horacio Capote Michelle Rainka Douglas W. Scharre Maria Kataki Anahita Adeli Earl A. Zimmerman Dzintra Celmins Alice D. Brown Godfrey D. Pearlson Karen Blank Karen Anderson Robert B. Santulli Tamar J. Kitzmiller Eben S, Schwartz Kaycee M. Sinks

Jeff D. Williamson Pradeep Garg Franklin Watkins Brian R. Ott Henry Querfurth Geoffry Tremont Stephen Salloway Paul Malloy Stephen Correia Howard J. Rosen Bruce L. Miller Jacob Mintzer Kenneth Spicer David Bachman Elizabether Pasternak Irina Rachiksky John Rogers Andrew Kertesz Nunzio Pomara Raymundo Hernando Antero Sarrael Susan K. Schultz Laura L. Boles Hyungsub Shim Karen E. Smith Norman Relkin Gloria Chaing Amanda Smith Kristin. Fargher Balebail A. Raj